Strontium malonate, Osteoporosis

Strontium malonate is a dual acting bone agent which stimulates bone formation & reduces bone resorption .  There have been a number of research studies.  Here are recent results:

1. Researchers in Denmark have studies it.  They are developing itas a novel orally available pharmaceutical for the treatment and prevention of osteoporosis. As part of this development the compound was administered in doses of 0 (placebo), 300, 1000 and 3000 mg/kg/day to beagle dogs for a period of 4 weeks.

They  measured the incorporation of strontium in bone, marrow and teeth in their study. . . .. Bone samples showed an approximately 80 fold increase in strontium content in the dogs treated with 300 mg/kg/day compared to placebo. The higher dose groups showed only marginally higher incorporation of strontium suggesting that saturation levels were reached with the lowest dose level.

More strontium malonate studies

Another study was reported at the European Calcified Tissue Society meeting.  It concluded that:

"All 3 doses of NB S101 were well-tolerated and significantly suppressed bone resorption while improving BMD. The results consistently show that NB S101 was safe and well tolerated and was effective on bone turnover and BMD in the short-term; it merits development as a treatment for postmenopausal osteoporosis"

Authors: K. Brixen,  K. Krogsgaard,  S. Christgau, , M. Weis ,, R. Eastell,  Dept of Endocrinology, Odense University Hospital, Odense, ; Phase OneTrials, Hvidovre Hospital, Hvidovre,  Research and development,  Clinical Development, Osteologix, Copenhagen, Denmark, Metabolic Bone Centre, Sheffield University, Sheffield, United Kingdom.

And in 2020 there was A review of the latest insights into the mechanism of action of strontium in bone published in Bone Reports, April 24.